Destiny Pharma
Skip to content
  • About Us
    • Board of Directors
    • Leadership
    • Scientific Advisory Board
    • History
  • Pipeline
    • NTCD-M3 for Clostridioides difficile Infections
    • XF-73 Nasal for Post Surgical Infections
    • XF-73 for Dermal Infections
    • SPOR-COV™ for COVID-19
    • XF Research Programs
  • Target Markets
    • Clostridioides difficile Infections
    • Post Surgical Infections
    • Dermal Infections
    • COVID-19
    • Anti-Microbial Resistance
  • Our Technologies
    • Biotherapeutics
      • NTCD-M3
      • SPOR-COV™
    • XF Platform
  • Business Development
  • News
  • Investors
    • AIM Rule 26
    • Corporate Governance
    • Share Price Information
    • Regulatory News
    • Constitutional Documents
    • Reports & Presentations
    • Advisers / Shareholder Contacts
    • Analyst Coverage
    • Email Alerts
  • Contact
    • Careers
    • Useful Links

Regulatory News

15 Aug 2019 – Change in Shareholding

Posted on 16/08/2019 by William Rhys-Williams

Information about a recent change can be found here.

Posted in News Regulatory News

Latest News

  • 27 Jan 2021 – Destiny Pharma welcomes Matt Hancock’s statement saying G7 will focus on AMR 27/01/2021
  • 21 Jan 2021 – Destiny Pharma Investor Presentation 21/01/2021
  • 06 Jan 2021 – Destiny Pharma appoints Stephanie Bewick as Chief Business Officer 06/01/2021

Events

  • Destiny Pharma to present at 14th Annual European Life Sciences CEO Forum, 10 – 11 March 2021 25/01/2021
  • Destiny Pharma to present at LSX World Congress, 1 – 5 February 2021 15/01/2021

Destiny Pharma

© All rights reserved.

Powered by WordPress

Destiny Pharma plc
Sussex Innovation Centre
Science Park Square
Brighton
BN1 9SB
UK

Tel: +44(0) 1273 704440

Registered Company
No. 3167025
About Us
Pipeline
Target Markets
Our Technologies
Business Development
News
Investors
Contact
Terms of Use
Privacy Statement